新冠病毒感染后肺纤维化药物治疗新进展  

Progress on the treatment of post-COVID-19 pulmonary fibrosis

作　　者：李世琪 彭丽[1] LI Shiqi;PENG Li(Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院呼吸与危重症医学科,重庆400016

出　　处：《现代医药卫生》2025年第3期783-788,共6页Journal of Modern Medicine & Health

摘　　要：新型冠状(新冠)病毒感染是全球面临的公共卫生危机,大量临床研究发现,新冠病毒感染后肺纤维化(PCPF)是新冠病毒感染最重要的并发症之一,通常需较长的康复期。目前,针对PCPF的治疗策略尚未形成统一标准。该文就PCPF的病理生理机制和药物治疗的临床探索和进展进行了综述,旨在为临床医生努力改善PCPF患者预后提供参考依据。The SARS-CoV-2 infection was a global public health crisis,and numerous clinical studies have found that post-COVID-19 pulmonary fibrosis(PCPF)is one of the most significant complications of COVID-19,typically requiring a long recovery period.Currently,there is no unified standard for the treatment strategy of PCPF.This article reviewed the pathophysiological mechanisms,clinical explorations,and advancements in drug treatments for PCPF,aiming to provide a reference for clinical doctors to improve the prognosis of PCPF.

关 键 词：新型冠状病毒 感染 肺纤维化 药物治疗 综述 

分 类 号：R563[医药卫生—呼吸系统]